Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Researchers Nyu Langone Health and his Cancer Cancer Perlmutter found that blood tests could predict return skin cancer.
Melanoma is a rarer form of skin cancer that is more dangerous than other varieties, according to American cancer society.
This is because it is much more likely to expand to other parts of the body if it is not found and treated early.
Cancer report reveals surprisingly new death data, diagnosis
New cancer surveyPublished in Lancet Oncology Journal, he examined the level of circulating tumor DNA (CTDNA) found in the blood of patients with cancer.
Approximately 80% of patients with melanoma in phase 3 who had a detectable level of CTDNA later experienced cancer return later. (East)
Approximately 80% of patients with melanoma in phase 3 who had a detectible CTDNA level (before they started treatment) later experienced the return of cancer later, according to a statement from NYU Langone.
Stage 3 melanoma – one of the most aggressive forms of skin cancer – occurs when Cancer spread to lymph nodes.
A popular coffee alternative can help prevent cancer, experts say
Lymph nodes can be surgically removed, but when they disappear, it makes it difficult to control cancer using traditional methods such as X -rays and CT scanning, researchers noted.
This challenge has encouraged an interest in finding new ways to discover cancer activities before.
Melanoma is a rarer form of skin cancer that is more dangerous than other varieties because of how fast it spreads. (East)
“Our discoveries suggest that DNA tests circulating tumor could help oncologists determine which patients with melanoma He will most likely respond well to therapy, “said the leading author Mahrukh Syeda in the edition.
Early detection of the return of the disease through the analysis of CTDNA could save lives, according to Syeda, because it is obviously difficult to treat this type of cancer after expanding.
“DNA tests in tumor circulation provide a clear, direct measure of the disease itself.”
The study analyzed the results of almost 600 men and women who participated in an earlier clinical trial. Researchers used blood samples to compare the presence of CTDNA and evidence of cancer return.
The team explained other factors such as gender, age and type of therapy used to fight cancer.
The usual medical test associated with 5% cancer, the study suggests: ‘use them wise’
Almost all patients who have had a detectable level of CTDNA within one year of treatment.
“The CTDNA method acts by focusing on the most common mutations in Genetic code In the melanoma cells, “the release states.
Almost all patients who had a detectsable level of CTDNA within a year of treatment experienced the return of melanoma, researchers revealed. (East)
The level of CTDNA levels was equally good or better in predicting relapse than other tests that include the testing of the tumor itself, researchers revealed.
“Unlike standard, tissue -based analyzes Tumor cellsWhat can suggest only the likelihood of relapse, circulating DNA tumor tests provide a clear, direct measure of the disease itself and can directly tell us that he has returned to Melano, “said Senior Author and dermatologist David Polsky in a press release.
Click here to sign up for our Health Bulletin
In some cases, however, the cancer is still returning even though patients had negative CTDNA tests before the start of therapy.
Researchers plan to improve test sensitivity in the next study in the hope of reducing cases like these.
“It is clear from this work and others that persistent circulating DNA tumors after curative surgery is a bad forecasting sign, suggesting a high risk for early relapse.” (East)
Dr. Joshua Strauss, attended a hematologist and medical oncologist at Advanced Care Oncology and Hematology Associates of the Atlantic Medical Group in Morristown, New Jersey, applauded to research.
Click here to get the Fox News app
“This is another in a series of studies that have advertised powerful technology which are now able to detect DNA tumors that circulate with blood in different types of tumors, “he told Fox News Digital.
For more health articles, visit www.foxnews.com/health
“From this paper and others it is clear that persistently circulates DNA tumors after a curative surgery is a bad prognostic sign, suggesting a high risk for early relapse, “Strauss continued.
The next step in the evolution of this technology, according to the oncologist, will be to use this data “not only in a prognostic way, but in a predictive way to help lead the management elections.”
